# A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/a-phase-ii-study-of-pembrolizumab-in-egfr-mutant-pd-l1-tyrosine-kinase-inhibitor/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Aaron Lisberg,Amy L. Cummings,Jonathan W. Goldman,Krikor Bornazyan,Nicholas Reese,T. Wang,Paul Coluzzi,Blanca Ledezma,Melody Mendenhall,J.S. Hunt,Brian R. Wolf,Benjamin Jones,John Madrigal,John M. Horton,Marshall L. Spiegel,James Carroll,Jaklin Gukasyan,T.J. Williams,L. Sauer,Courtney Wells,Ariana Hardy,Paulina Linares,Chong-Hee Lim,Lin Ma,Carlos Adame,Edward B. Garon |
| Citations | 596 |
| DOI | 10.1016/j.jtho.2018.03.035 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | http://www.jto.org/article/S1556086418306026/pdf |
| OpenAlex ID | https://openalex.org/W2889653218 |
| PMID | 29874546 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Aaron Lisberg](https://scholariq.org/researchers/aaron-lisberg/)
- [Jonathan W. Goldman](https://scholariq.org/researchers/jonathan-w-goldman/)
- [Edward B. Garon](https://scholariq.org/researchers/edward-b-garon/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.